摘要
目的:探讨新辅助化疗前后Survivin、MRP1在宫颈鳞癌组织中的表达及其与化疗敏感性的关系。方法:采用免疫组化SP法对38例宫颈鳞癌患者新辅助化疗(NACT)前后MRP1、Survivin的表达水平进行检测。结果:NACT前Survivin的阳性表达率(63.16%)显著高于NACT后(39.47%)(P<0.05),且NACT前Survivin表达阴性者化疗有效率(92.86%)高于表达阳性者(62.50%)(P<0.05)。Survivin的表达水平与宫颈鳞癌的分化程度相关(P<0.05),但与年龄、临床分期不相关(P>0.05)。新辅助化疗前后MRP1在宫颈鳞癌中的阳性表达率分别为84.21%和92.11%,两者间无显著性差异(P>0.05),且化疗前MRP1表达阴性者与表达阳性者化疗有效率分别为83.33%、71.88%,两者间无显著性差异(P>0.05)。MRP1的表达与宫颈癌的临床分期、分化程度、年龄均不相关(P>0.05)。结论:Survivin、MRP1在宫颈鳞癌组织中均有较高的表达水平,但只有Survivin的表达水平与NACT疗效具有显著的相关性,Survivin的表达水平可作为预测宫颈鳞癌对化疗敏感性的指标。
Objective： To investigate the expression of Survivin and multiple resistance - associated protein - 1 （ MRP1 ） in cervical squamous cancer before and after neoadjuvant chemotherapy（NACT） and its relation with tumor chemosensitivity and related clinical pathological factors. Methods：The specimens of 38 patients with cervical squa- mous cancer before and after NACT were examined by SP immunohistoehemistry. The correlation between Survivin and MRP1 expression and therapeutic effect was analyzed. Results：Survivin positive expression rate in cervical squamous cancer before NACT was 63.16% , which was significantly higher than that after NACT （39.47%） （P 〈 0.05 ）. The effective rate of patient with Survivin negative expression before NACT was 92.86% , which was significantly higher than of patient with Survivin positive expression（ 62.50% ） （ P 〈 0.05 ）. Survivin expression levels were negatively re- lated to the differentiation of the tumor（ P 〈 0.05 ）, but not related to age and clinical stages（ P 〉 0.05 ）. MRP1 posi- tive expression rates in cervical cancer before and after NACT were 84.21% and 92.11% respectively and the differ- ence was not significant（ P 〉 0.05 ）. The effective rates of patient with MRP1 negative expression in cervical squa- mous cancer before chemotherapy were 83.33% and 71.88% respectively and the difference was not significant（ P 〉 0.05 ）. MRP1 expression levels were not related to clinical stages, differentiation of the tumor or age （ P 〉 0.05 ）. Conclusion：The expression levels of Survivin, MRP1 were higherin cervical squamous cell carcinoma,but only Sur- vivin expression levels are significantly associated with response to chemotherapy and it can be used as a predictive marker of the sensitivity to NACT in patients with cervical squamous cancer.
出处
《现代肿瘤医学》
CAS
2014年第4期889-891,共3页
Journal of Modern Oncology
基金
湖南省郴州市科技计划项目(编号:201206)
湘南学院科学研究项目(编号:201253)
关键词
宫颈癌
新辅助化疗
生存素
多药耐药相关蛋白1
化疗敏感性
cervical cancer
neoadjuvant chemotherapy
Su^ivin
muhiple resistance- associated protein- 1
chem-osensitivity
作者简介
邓亚丽（1961-），女，湖南人，教授，主任医师，主要从事妇科肿瘤及生殖内分泌研究工作。E—mml：ddyyll@163．com
